Kodiak Sciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
32.1%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$4.00next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| PEAK Phase 3 Topline Results (KSI-101 in MESI) | 25 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly169.5MTarget: Sufficient to fund operations into 2027
Zenkuda (tarcocimab tedromer) Phase 3 GLOW2 DRSS Response Rate Annually6,250.0%Target: Statistically superior to sham (3.3%)
Quarterly Net Loss Quarterly-58.2MTarget: Manageable cash burn within runway limits
Watch Items
- DAYBREAK Phase 3 Topline Data ReadoutTrigger: September 2026Action: Evaluate efficacy and safety of Zenkuda and KSI-501 in treatment-naive wet AMD to support BLA filing.
- KSI-101 Phase 3 PEAK Topline Data ReadoutTrigger: 4Q 2026 (expected before Christmas)Action: Assess primary efficacy endpoints in macular edema secondary to inflammation (MESI).
- Multi-Indication BLA Submission TimelineTrigger: Late 2026 to 2027Action: Monitor regulatory readiness and filing progress for Zenkuda across diabetic retinopathy, RVO, and wet AMD.
Research as of 20 Jun 2026